Predictive Oncology Inc. (NASDAQ:POAI) Short Interest Down 26.1% in February

Predictive Oncology Inc. (NASDAQ:POAI) was the recipient of a significant decline in short interest in February. As of February 15th, there was short interest totalling 463,100 shares, a decline of 26.1% from the January 31st total of 626,700 shares. Based on an average trading volume of 2,000,000 shares, the short-interest ratio is currently 0.2 days. Currently, 6.5% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Predictive Oncology in a research note on Friday, November 15th.

Predictive Oncology Stock Performance

NASDAQ:POAI traded up $0.03 during trading hours on Tuesday, reaching $1.29. The company’s stock had a trading volume of 118,035 shares, compared to its average volume of 1,695,753. The company has a market capitalization of $8.83 million, a P/E ratio of -0.42 and a beta of 1.25. Predictive Oncology has a 12 month low of $0.55 and a 12 month high of $3.11. The stock has a 50 day moving average price of $1.34 and a two-hundred day moving average price of $0.98.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.